argenx 股票：上调至“买入”评级，VYVGART 增长周期仍具潜力 (NASDAQ:ARGX)
· seekingalpha.com
将 argenx (ARGX) 评级上调至“买入”，目标价为 1,050 美元：VYVGART 的增长、标签扩展、强劲的利润率及管线潜力。点击查看更多详情。
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...